주요기술
주요기술
주요기술
Novel Protein Drug for Stroke
작성자 | 김상훈 | 카테고리 | 세브란스병원 |
---|---|---|---|
작성일 | 2016-12-27 | 조회수 | 7,403 |
Novel Protein Drug for Stroke
개발자
허지회 교수(MD, Ph.D, Dept. Neurology)
기술개요
Intravenous (IV) administration of recombinant tissue plasminogen activator (rt-PA) is an effective treatment for ischemic stroke if administered within 4.5 hours of symptom onset. However, more than two-thirds of patients fail to achieve successful recanalization after IV rt-PA treatment. rt-PA also has neurotoxic effects. To improve thrombolytic potency and reduce the potential adverse effects of rt-PA, several new thrombolytic agents have been developed. However, up to now, there has not been prososed clinically satisfactory drugs for ischemic stroke. Accordingly, there remains a long-felt need in new drugs for ischemic stroke with enhanced thromobolysis activity and safety that have other mode of action than fibrinolysis.
기술설명

기술특징
- The protein drug candidate exhibits stroke treatment by dual functions including thrombolysis and suppression of neuroinflammation. Such dual treatment approaches by a single API (active pharmaceutical ingredient) are very unique and effective in stroke treatment.
- The stroke therapy of the protein drug candidate is accomplished by the mode of action, thrombolysis through binding to integrins on platelets (e.g., GP IIb/IIIa) and suppression of neuroinflammation through binding to integrins on neutrophils (e.g., αMβ2andαLβ2).
- The protein drug candidate has been validated to exhibit good safety in mouse model. In particular, bleed complications were not observed in the treatment group
- The protein drug candidate can be produced using our Pichia exprssion system with good mass productivity for clinical tests and commercialization.
활용분야
Acute Ischemic Stroke: Global Market Value to Grow Significantly by 2017
- The acute ischemic stroke (AIS) therapeutics market in the six major countries - the US, France, Germany, Italy, Spain and UK - is forecast to jump from $531m in 2012 to $1.2 billion by 2017, at a Compound Annual Growth Rate (CAGR) of 17.3%.
- The US market will continue to generate the majority of sales, more than doubling its revenue from $376.4m in 2012 to $945.4m by 2017, at a CAGR of 20.2%. This is due to the US

연락처
- 담당자 : 장규진
- 소속 : 연세의료원 산학협력단
- 이메일 : kjjang@yuhs.ac.kr
- 연락처 : 02-2228-0295
- 이전글 RIP3-MLKL 경로 차단제 활용한 피부 네크롭토시스 질환 치료
- 다음글 A Composition for Promoting Chondrogenesis from Stem Cells